Description: Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Home Page: vcel.com
64 Sidney Street
Cambridge,
MA
02139
United States
Phone:
617 588 5555
Officers
| Name | Title |
|---|---|
| Mr. Dominick C. Colangelo Esq. | CEO, President & Director |
| Mr. Joseph Anthony Mara Jr. | CFO & Treasurer |
| Mr. Michael Halpin | Chief Operating Officer |
| Mr. Sean C. Flynn | Chief Legal Officer |
| Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer |
| Mr. Jonathan D. Siegal | Principal Accounting Officer, VP & Corporate Controller |
| Mr. Eric Burns | Vice President of Finance & Investor Relations |
| Mr. Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy |
| Mr. Patrick Helfrich | Vice President of Marketing & Commercial Strategy |
| Mr. Mike Gilligan | Senior Vice President of Sales |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 106.383 |
|---|---|
| Trailing PE: | 757.1429 |
| Price-to-Book MRQ: | 10.755 |
| Price-to-Sales TTM: | 11.699 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 314 |